ICS 11.020 C 05 团体标准 T/GDACM 0102 —2021 原发性骨质疏松症（骨痿） 中医临床诊疗指南 Chinese medicine guideline s for the diagnosis and treatment of primary osteoporosis （Gu Wei disease） 2021- 3 - 3 发布 2021 – 3 - 3 实施 广 东 省 中 医 药 学 会 发布 全国团体标准信息平台 全国团体标准信息平台 T/GDACM 0102 —2021 I 目 次 前言 ................................ ................................ ................................ ................................ ................ III 引言 ................................ ................................ ................................ ................................ ................ IV 1 范围 ................................ ................................ ................................ ................................ ............. 1 2 规范性引用文件 ................................ ................................ ................................ ......................... 1 3 术语和定义 ................................ ................................ ................................ ................................ . 1 4 诊断 ................................ ................................ ................................ ................................ ............. 1 4.1 临床表现 ................................ ................................ ................................ .......................... 1 4.2 辅助检查 ................................ ................................ ................................ .......................... 2 4.3 西医诊断 ................................ ................................ ................................ .......................... 2 4.4 中医诊断证候诊断（中医辨证分型） ................................ ................................ .......... 3 5 中医治疗方案 ................................ ................................ ................................ ............................. 4 5.1 内治法（辨证论治） ................................ ................................ ................................ ...... 4 5.2 外治法 ................................ ................................ ................................ .............................. 4 5.3 其它 ................................ ................................ ................................ ................................ .. 5 6 药物干预的质量控制标准 ................................ ................................ ................................ ......... 5 6.1 严格遵照每种药物的适应症和禁忌 症、用法、用量和注意事项 .............................. 5 6.2 实施过程要结合病人的个体情况加以调整 ................................ ................................ .. 5 6.3 监测与随访 ................................ ................................ ................................ ...................... 5 7 疗效判定 ................................ ................................ ................................ ................................ ..... 6 7.1 观察指标 ................................ ................................ ................................ .......................... 6 7.2 安全性指标 ................................ ................................ ................................ ...................... 6 7.3 疗效性指标 ................................ ................................ ................................ ...................... 6 8 临床诊疗 ................................ ................................ ................................ ................................ ..... 7 8.1 诊疗流程 ................................ ................................ ................................ .......................... 7 8.2 临床路径（试行） ................................ ................................ ................................ .......... 7 附 录 A （资料性） 骨质疏松症评分工具 ................................ ................................ ............ 8 附 录 B （资料性） 临床诊疗流程 ................................ ................................ ...................... 10 附 录 C （资料性） 临床表单 ...............